ClinicalTrials.gg
CompletedNCT06479161Updated Oct 29, 2026

Effects of Oral Tranexamic Acid Following Total Knee Arthroplasty

A Phase 2 interventional study of Tranexamic acid in Postoperative Pain, sponsored by Matthew Grosso, MD. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Matthew Grosso, MD · Phase 2, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Enrollment
484th of 1,099
86 · median 76
Started
2024
with 63 others
Phase 2
122 of 1,181
10 open now
Registered
1,038th of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 484th largest by enrollment of the 1,099 interventional ones that give a count, is one of 64 that started in 2024, is one of 122 in phase 2, and was the 1,038th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

199 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate postoperative pain. Secondary outcomes evaluated in this study will include range of motion (ROM), opioid consumption, and ambulation. Each outcome measure will be evaluated, oral tranexamic acid (TXA) in the experiment arm and placebo in the control arm, after total knee arthroplasty (TKA) at postoperative days 0-3, and weeks 1, 2, 6, and 12.

Read the detailed description

Randomized controlled trial with 1:1 allocation, selected through computer-based randomization.

This study will review prospectively collected data, including patient demographic information, surgeon, use of oral tranexamic acid (TXA) or placebo regimen, and postoperative outcomes up to 3 months after surgery. Collaboration with Saint Francis' pharmacy team will be performed to ensure appropriate blinded administering of the oral TXA and placebo medication.

This will be a double blinded study, with both patient and surgeon blinded to study group.

6.0 TXA dosing protocol TXA day of surgery [All patients]

  • Administer 1-gram IV TXA intraoperatively at the start of the case (hold for history of stent within 1 year of surgery)

    o AND

  • Administer 1-gram IV TXA postoperatively before leaving PACU (hold for history of stent within 1 year of surgery)

    o OR

  • Exception: Administer 2 grams TXA in 50cc normal saline topically during the case for patients with a history of stent placed within one year of surgery.

TXA postoperative day (POD) 1-3 [Experimental group]

  • Administer 1.95 grams oral (3- 650 mg tablets) TXA each morning for three days following surgery.
  • Patients discharged home before POD 3 will be sent home with remaining oral TXA doses.

Placebo POD 1-3 [Control group]

  • Administer oral placebo (3 tablets) each morning for three days following surgery.
  • Patients discharged home before POD 3 will be sent home with remaining oral placebo doses.
03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • - All patients undergoing either manual or robotic primary total knee arthroplasty (TKA)
  • Performed by participating Connecticut Joint Replacement Institute (CJRI) surgeons (Dr. Matthew Grosso, Dr. Robert McAllister, Dr. Chad Daniel, Dr. Eric Silverstein, Dr. Alex Dukas, Dr. Michael Joyce, Dr. Brett Wasserlauf).
  • Male and female patient age 18-89
  • Primary diagnosis of knee osteoarthritis

Exclusion Criteria:

  • Revision TKA
  • No exclusion based on gender
  • Patients \<18 and >89 years old
  • Exclusion for IV oral tranexamic acid (TXA):

    • TXA allergy - there are NO absolute for TXA use.
    • History of stent placed within one year of surgery - patient will receive topical TXA as an alternative.
  • Exclusion for oral TXA:

    o Actively treated cancer or deep vein thrombosis (DVT)

  • Chronic opioid use (opioid use within the 4 weeks prior to surgery)
  • Allergies to nonsteroidal Anti-inflammatory drugs (NSAIDs) and acetaminophen
  • Patients with drug interactions
  • Pre-existing neuropathy
  • Current or previous venous thrombosis (DVT or venous stasis disease)
  • Immuno-compromised secondary to medical condition
  • Immune-suppressive medications, chemotherapy
  • Pregnancy, breast feeding
  • History of pain catastrophizing. Major depressive disorder
  • History of suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  • Currently on a neuroleptic agent [e.g., gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) etc.].
  • Non-English speaking and reading patient populations
  • Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that, in the opinion of the investigator, renders the subject medically unstable or complicates the subject's post-operative course.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Active comparator
    TXA

    \- 1.95 grams oral TXA (tranexamic acid) (3- 650 mg tablets) administered postop day one, postop day two and postop day three. Compounded by registered pharmacist and labeled with subject name and instructions for use.

    Drug: Tranexamic acid

  • Placebo comparator
    Placebo

    \- 3 tablets administered postop day one, postop day two and postop day three. Compounded by registered pharmacist and labeled with subject name and instructions for use.

    Drug: Tranexamic acid

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS) Pain scores

    Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain. Higher scores are a worse outcome.

    Time frame: postoperative day (POD) 0, 1, 2, 3 (+/- 0 days) and weeks 1 (+/- 0 days), 2 (+/- 2 days), 6 and 12 (+/- 7 days).

Secondary outcomes

  1. Range of Motion

    Clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion

    Time frame: at 2, 6 and 12 week follow up visits

  2. Opioid consumption

    Subjects will keep a log recording opioid consumption. Research staff will ask subjects to report opioids during postoperative telephone calls.

    Time frame: POD 1, 2, 3 (+/- 0 days) and weeks 1 (+/- 0 days), 2 (+/- 2 days), 6 and 12 (+/- 7 days)

  3. Ambulation Status

    Surgeon or physical therapist will record if patient is using a walker, cane or no assistive devices.

    Time frame: at 2, 6 and 12 week follow up visits

07

Study locations

1 site
  • Trinity Health Of New England/CT Joint Replacement Institute
    Hartford, Connecticut 06105, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Feb 2026, 20 months.

Of 90 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 20 months is close to that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Feb 2025 → Feb 2026 and completion Mar 2025 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jun 28, 2024
StartActual
Jun 10, 2024
Primary completionActual
Feb 19, 2026was Feb 2025
CompletionActual
Feb 19, 2026was Mar 2025
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Primary completion
Feb 28, 2025→Feb 19, 2026 (actual)
Oct 29, 2026
Study completion
Mar 30, 2025→Feb 19, 2026 (actual)
Oct 29, 2026
Enrollment
80 (estimated)→86 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Primary completion Feb 28, 2025→Feb 19, 2026 (now actual)
    Study completion Mar 30, 2025→Feb 19, 2026 (now actual)
    Enrollment 80 (estimated)→86 (actual)
    + 5 other changes: index terms, arm descriptions, criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06479161
Lead sponsor
Matthew Grosso, MD
Responsible party
Matthew Grosso, MD (Director, Quality and Outcomes Research, Trinity Health Of New England) — Sponsor-investigator
First posted
Jun 28, 2024
Start date
Jun 10, 2024
Primary completion
Feb 19, 2026
Completion
Feb 19, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion